EMBC logo

Embecta (EMBC) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

22 March 2022

Indexes:

Not included

Description:

Embecta, formerly part of BD, specializes in diabetes care products, particularly insulin delivery systems and pen needles. The company focuses on improving the lives of people with diabetes by providing innovative, reliable, and easy-to-use solutions for managing their condition effectively.

Key Details

Price

$20.00

TTM Dividend Yield

3.00%(-8.54% YoY)

Annual Revenue

$1.12 B(+0.21% YoY)

Annual EPS

$1.34(+9.84% YoY)

PE Ratio

14.81(-23.06% YoY)

Annual ROE

-10.61%

Beta

1.09

Events Calendar

Earnings

Next earnings date:

Feb 07, 2025

Recent quarterly earnings:

Nov 26, 2024

Recent annual earnings:

Nov 26, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

Dec 06, 2024
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

27 Nov '24 BTIG
Buy
15 July '24 Morgan Stanley
Underweight
10 May '24 Morgan Stanley
Underweight
22 Nov '23 Morgan Stanley
Underweight
18 Oct '23 Morgan Stanley
Underweight
24 Aug '23 Morgan Stanley
Underweight
18 July '23 Morgan Stanley
Underweight
15 May '23 Morgan Stanley
Underweight
06 Jan '23 Morgan Stanley
Underweight
21 Dec '22 Morgan Stanley
Equal-Weight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

New Initiatives Expected To Make Embecta More Profitable
New Initiatives Expected To Make Embecta More Profitable
New Initiatives Expected To Make Embecta More Profitable
EMBC
seekingalpha.com04 December 2024

Embecta Corp.'s Q4 results showed significant net income and EPS growth as well as profitability plans, and drove up the share price. The company announced a restructuring plan to streamline operations, reduce costs by up to $65 million annually, and discontinue its insulin patch pump program. Embecta aims to strengthen its core business, expand its GLP-1 therapies portfolio, and reduce debt, positioning it for profitable growth in fiscal 2025.

New Strong Buy Stocks for December 2nd
New Strong Buy Stocks for December 2nd
New Strong Buy Stocks for December 2nd
EMBC
zacks.com02 December 2024

EMBC, TOST, MNDY, NTRS and MANU have been added to the Zacks Rank #1 (Strong Buy) List on December 2, 2024.

Overlooked Stock: EMBC
Overlooked Stock: EMBC
Overlooked Stock: EMBC
EMBC
youtube.com27 November 2024

Bad news is good news? Appears to be the case for medical device company Embecta (EMBC) as shares soared after it stopped its insulin patch pump program.

Embecta Corp. (EMBC) Q4 2024 Earnings Call Transcript
Embecta Corp. (EMBC) Q4 2024 Earnings Call Transcript
Embecta Corp. (EMBC) Q4 2024 Earnings Call Transcript
EMBC
seekingalpha.com26 November 2024

Embecta Corp. (NASDAQ:EMBC ) Q4 2024 Earnings Conference Call November 26, 2024 8:00 AM ET Company Participants Pravesh Khandelwal - VP of IR Dev Kurdikar - President and CEO Jake Elguicze - CFO Conference Call Participants Marie Thibault - BTIG Operator Good day, and welcome to the Embecta Fourth Quarter of Fiscal Year 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps
Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps
Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps
EMBC
benzinga.com26 November 2024

On Tuesday, Embecta Corp EMBC posted the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents and down from 59 cents reported a year ago.

Embecta Corp. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2025 Financial Guidance; Discontinues Insulin Patch Pump Program; and Announces Restructuring to Streamline Operations and Reduce Costs
Embecta Corp. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2025 Financial Guidance; Discontinues Insulin Patch Pump Program; and Announces Restructuring to Streamline Operations and Reduce Costs
Embecta Corp. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2025 Financial Guidance; Discontinues Insulin Patch Pump Program; and Announces Restructuring to Streamline Operations and Reduce Costs
EMBC
globenewswire.com26 November 2024

PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2024.

embecta Announces Quarterly Cash Dividend
embecta Announces Quarterly Cash Dividend
embecta Announces Quarterly Cash Dividend
EMBC
globenewswire.com26 November 2024

PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on December 18, 2024 to stockholders of record at the close of business on December 6, 2024.

UPDATE - embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results
UPDATE - embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results
UPDATE - embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results
EMBC
globenewswire.com12 November 2024

PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal fourth quarter and full year 2024 financial results, and provide an operational update, including preliminary fiscal year 2025 financial guidance, at 8:00 a.m. Eastern Time (ET) on Tuesday, November 26, 2024.

embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results
embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results
embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results
EMBC
globenewswire.com12 November 2024

PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal fourth quarter and full year 2024 financial results, and provide an operational update, including preliminary fiscal year 2025 financial guidance, at 8:00 a.m. Eastern Time (ET) on Thursday, November 26, 2024.

Embecta Stock Gains on FDA Clearance for Type 2 Diabetes Insulin Pump
Embecta Stock Gains on FDA Clearance for Type 2 Diabetes Insulin Pump
Embecta Stock Gains on FDA Clearance for Type 2 Diabetes Insulin Pump
EMBC
zacks.com04 September 2024

EMBC's shares close higher following FDA clearance for its disposable patch pump for insulin delivery, expanding the target market with its availability for type 2 diabetes.

FAQ

  • What is the primary business of Embecta?
  • What is the ticker symbol for Embecta?
  • Does Embecta pay dividends?
  • What sector is Embecta in?
  • What industry is Embecta in?
  • What country is Embecta based in?
  • When did Embecta go public?
  • Is Embecta in the S&P 500?
  • Is Embecta in the NASDAQ 100?
  • Is Embecta in the Dow Jones?
  • When was Embecta's last earnings report?
  • When does Embecta report earnings?
  • Should I buy Embecta stock now?

What is the primary business of Embecta?

Embecta, formerly part of BD, specializes in diabetes care products, particularly insulin delivery systems and pen needles. The company focuses on improving the lives of people with diabetes by providing innovative, reliable, and easy-to-use solutions for managing their condition effectively.

What is the ticker symbol for Embecta?

The ticker symbol for Embecta is NASDAQ:EMBC

Does Embecta pay dividends?

Yes, Embecta pays dividends. The last payment was $0.15, with an ex-dividend date on 06 December 2024

What sector is Embecta in?

Embecta is in the Healthcare sector

What industry is Embecta in?

Embecta is in the Medical Instruments & Supplies industry

What country is Embecta based in?

Embecta is headquartered in United States

When did Embecta go public?

Embecta's initial public offering (IPO) was on 22 March 2022

Is Embecta in the S&P 500?

No, Embecta is not included in the S&P 500 index

Is Embecta in the NASDAQ 100?

No, Embecta is not included in the NASDAQ 100 index

Is Embecta in the Dow Jones?

No, Embecta is not included in the Dow Jones index

When was Embecta's last earnings report?

Embecta's most recent earnings report was on 26 November 2024

When does Embecta report earnings?

The next expected earnings date for Embecta is 7 February 2025

Should I buy Embecta stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions